Aligos Therapeutics Inc
(ALGS)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2019 | 12-2018 | 12-2017 | 12-2006 | |
| Cash Flows From Operating Activities | ||||
| Net Income | -52,264 | -13,933 | N/A | N/A |
| Depreciation Amortization | 1,422 | 1,740 | N/A | N/A |
| Accounts payable and accrued liabilities | 4,607 | 6,163 | N/A | N/A |
| Other Working Capital | 3,671 | 4,885 | N/A | N/A |
| Other Operating Activity | -4,203 | -4,904 | 0 | 0 |
| Operating Cash Flow | $-46,767 | $-6,049 | $N/A | $N/A |
| Cash Flows From Investing Activities | ||||
| Change In Deposits | 19,596 | -66,773 | N/A | N/A |
| PPE Investments | -2,786 | -2,516 | N/A | N/A |
| Purchase Of Investment | -10,019 | N/A | N/A | N/A |
| Investing Cash Flow | $6,791 | $-69,289 | $N/A | $N/A |
| Cash Flows From Financing Activities | ||||
| Debt Issued | N/A | 5,001 | N/A | N/A |
| Debt Repayment | -43 | -1 | N/A | N/A |
| Common Stock Issued | 612 | 79 | N/A | N/A |
| Other Financing Activity | 84,963 | 94,806 | 0 | 0 |
| Financing Cash Flow | $85,532 | $99,885 | $N/A | $N/A |
| Beginning Cash Position | 24,547 | 0 | N/A | N/A |
| End Cash Position | 70,103 | 24,547 | N/A | N/A |
| Net Cash Flow | $45,556 | $24,547 | $N/A | $N/A |
| Free Cash Flow | ||||
| Operating Cash Flow | -46,767 | -6,049 | N/A | N/A |
| Capital Expenditure | -2,786 | -2,516 | N/A | N/A |
| Free Cash Flow | -49,553 | -8,565 | 0 | 0 |